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Introduction
The epidermal growth factor (EGF) receptor (EGFR) is a mem-
ber of the ErbB family, consisting of four closely-related tyro-
sine kinase receptors, which affects cell proliferation. It includes 
EGFR family members HER-1 (Erb-1), EGFR-2/HER-2 (Erb-
2), HER-3 (Erb-3) and HER-4 (Erb-4). EGFR-1 and HER-2 are 
overexpressed in several carcinomas with high levels of expres-
sion being a prominent feature of the malignant phenotype in 
many solid human tumors,1 including breast cancer. EGFR-1 
activation occurs through four different ligands, most commonly 
EGF and transforming growth factor-α (TGFα), which form 
homodimeric complexes or heterodimeric complexes, preferably 
with HER-2, as well as with other members of the ErbB family 
of receptors.
Ligand binding and dimerization cause autophosphorylation 
of the intracytoplasmic domains and activation of the intracel-
lular tyrosine kinase. Activated EGFR (phosphorylated EGFR 
[pEGFR]) stimulates several different signal transduction path-
ways, such as the MAPK/ERK and the phosphoinositide-3 kinase 
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(PI3K)/Akt pathways that lead to uncontrolled cell proliferation 
and inhibition of apoptosis. Although EGFR has not provided 
a useful prognostic/predictive marker of clinical response to 
EGFR-targeted therapies,2,3 other prognostic/predictive mark-
ers have been proposed, including the activated form of EGFR 
(pEGFR).4 Previously, EGFR phosphorylation was shown to be 
associated with poor prognosis in non-small-cell lung cancer and 
has been proposed as an important predictor of clinical outcome.5 
Thus, therapies targeting EGFR signaling by blocking phospho-
rylation of EGFR and its downstream target molecules may be 
required to control the pathogenesis and progression of EGFR 
overexpressed breast cancers.
Vascular endothelial growth factor receptor (VEGFR) is 
also a member of the receptor tyrosine kinase (RTK) family, 
which includes VEGFR-1 (flt-1), VEGFR-2 (KDR/flk-1) and 
VEGFR-3 (flt-4) and a soluble form of VEGFR-1 (sVEGFR-1), a 
negative regulator of VEGF.6 VEGFR-2 is proposed to function 
as a dominant receptor of VEGF/VEGFR signaling in the angio-
genesis pathway. It plays a central role in both local tumor growth 
and distant metastasis in breast cancer.7 Enhanced expression of 
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T-47D and ZR-75-1 in a dose-dependent manner and the cell 
inhibition was prominent mainly between concentrations of 
1–10 µM (Fig. 1A). The IC
50
 values of ZD6474 in MCF-7, 
MDA-MB-231, T-47D and ZR-75-1 cells were 12.667 ± 0.667, 
6.128 ± 0.446, 6.199 ± 0.356, 6.841 ± 0.237 and 5.6777 ± 0.487 
µM respectively.
ZD6474 induces cell cycle arrest at the G
0
-G
1
 phase. ZD6474 
induced cell cycle arrest at the G
0
-G
1
 phase, as shown in Figure 
1B. There was 20% relative increase in the G
0
-G
1
 phase in all 
breast cancer cells treated with ZD6474 for 24 h as compared 
with control cultures. This increase in G
0
-G
1
 phase was time-
dependent as shown in Table 1. There was a temporal decrease in 
cyclin D1 and cyclin E (Fig. 1C) with time, further confirming 
the role of ZD6474 in cell cycle arrest at the G
0
-G
1
 phase.
ZD6474 induces apoptosis in breast cancer cells. Apoptosis 
induction occurred in a time-dependent manner following 
ZD6474 treatment (Fig. 2A). ZD6474 induced more than 50% 
apoptosis after 72 h of treatment as quantified by flow-cytometry. 
This induction of programmed cell death was corroborated by 
DNA ladder formation in agarose gel electrophoresis (Fig. 2B). 
Oligonucleosomes were also observed under fluorescent micros-
copy after PI staining (Fig. 2C). Cleavage of poly(ADP-ribose) 
Polymerase (PARP) was also observed over time. Additionally, 
there was an increase in the pro-apoptotic Bax protein and a 
decrease in the anti-apoptotic Bcl-2 protein in a time-depen-
dent manner in MCF-7, MDA-MB-231, ZR-75-1 and T-47D 
cells (Fig. 2D). A decrease in the inactive pro-form (32 Kd.) 
of caspase 3 was also observed with time, indicating the role of 
effector caspase 3 in DNA fragmentation and apoptosis induc-
tion in MDA-MB-231, T-47D and ZR-75-1 cells. Caspase-3 is 
absent in MCF-7, indicating the contribution of other caspases in 
DNA fragmentation. There was no change in expression of p53 
(Fig. 3A), indicating that ZD6474 executed its apoptotic mecha-
nism independent of the p53 pathway.
ZD6474 inhibits epidermal growth factor receptor and 
vascular endothelial growth factor receptor signaling in 
breast cancer cells. The expressions of EGFR and VEGFR-2 did 
not change in a temporal manner in MCF-7 and MDA-MB-231 
cells (Fig. 3A). EGFR and VEGFR-2 remain unaltered even after 
72 h of ZD6474 treatment. Next, we determined whether 
ZD6474 could inhibit the phosphorylation of EGF-mediated 
growth and survival signaling pathways in breast cancer cells 
growing in culture. Western blots revealed inhibition by ZD6474 
of EGFR and VEGFR-2 phosphorylation, which was most pro-
nounced in MCF-7, T-47D and MDA-MB-231 cells (Fig. 3B). 
The phosphorylated forms of both Akt and MAPK were also 
down-modulated in cells treated with ZD6474. Total levels of 
EGFR, VEGFR-2, Akt and MAPK protein remained unaltered 
by ZD6474 treatment (Fig. 3B).
ZD6474 inhibits colony formation, chemoinvasion and 
angiogenesis. The effect of ZD6474 on the capacity of MCF-7, 
T-47D and MDA-MB-231 to grow in a semisolid medium was 
determined. MCF-7, T-47D and MDA-MB-231 formed colo-
nies which were further stimulated by EGF and ZD6474 inhib-
ited EGF stimulated colony formation in soft agar (Fig. 4A and 
B). Tumor cell migration is a critical factor in the formation of 
VEGF generally correlates with increased neovascularization as 
measured by microvessel counts within the tumor. Expression of 
VEGF and other pro-angiogenesis factors and their receptors cor-
relates with less favorable clinical outcomes in various cancers, 
including breast.8-11
Clinical trials with angiogenesis inhibitors targeting only the 
VEGF/VEGFR signaling pathway have been disappointing sug-
gesting that additional inhibitors may be necessary to inhibit tumor 
growth and proliferation. There are common downstream signal-
ing molecules involved in both EGFR- and VEGFR-mediated 
pathways. Specific cancer cells acquire resistance to anti-EGF/
EGFR therapy by increased tumor-induced angiogenesis due to 
the constitutive overexpression of VEGF.12 Additionally, activa-
tion of the EGFR signaling pathway also upregulates the produc-
tion of VEGF. Therefore, both pathways represent viable targets 
for therapy, and because of their parallel and reciprocal activa-
tion, dual inhibition of the EGF(R) and VEGF(R) signaling may 
result in significant anti-tumor activity. Several preclinical and in 
vitro studies demonstrate the additive effect of combining EGFR 
and VEGFR inhibitors in reducing tumor growth.13-15 Clinically, 
bevacizumab, a humanized antibody against VEGF, has shown 
considerable promise and improved survival for patients with col-
orectal, breast or lung cancer when used in combination with 
EGFR inhibitors or other chemotherapeutic drugs.15,16
The potential of dual targeting inhibitors as anti-cancer drugs 
has led to the clinical testing of ZD6474, a dual tyrosine kinase 
inhibitor (TKI) of EGFR and VEGFR-2, in various tumors. 
ZD6474 inhibits both the development of the tumor’s blood sup-
ply through inhibition of VEGFR (anti-angiogenesis) and tumor 
cell proliferation and survival through inhibition of EGFR. It 
also inhibits oncogenic RET kinases in thyroid cancers. Apart 
from inhibiting the phosphorylation of tyrosine kinases, it also 
inhibits serine-threonine kinases.17,18 ZD6474 is currently in 
phase III clinical trials for the treatment of follicular, medullary, 
anaplastic and locally advanced and metastatic papillary thyroid 
cancer, as well as for non-small cell lung cancer. Breast cancers 
display aggressive properties and are characterized by overexpres-
sion of EGFR and VEGFR. Despite improvements in chemother-
apy, the long-term survival of patients with advanced and higher 
stage breast cancer has remained very low. The present study has 
tested the hypothesis that simultaneous inhibition of phosphory-
lation of both EGFR and VEGFR pathways by ZD6474 would 
improve breast cancer outcome, particularly in EGFR and/or 
VEGFR expressing advanced breast cancers. Studies have now 
been conducted to test this possibility using breast cancer cell 
lines in vitro, MCF-7, T-47D, ZR-75-1 and MDA-MB-231, and 
in a MDA-MB-231 orthothopic nude mouse model. These stud-
ies confirm significant activity of ZD6474 in inhibiting growth 
and inducing apoptosis both in vitro and in vivo providing sup-
port for the use of this agent for the therapy of breast cancer.
Results
ZD6474 suppresses the in vitro cell proliferation of breast 
cancer cells in a dose-dependent manner. ZD6474 inhibited 
cell proliferation of breast cancer cells MCF-7, MDA-MB-231, 
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solid tumors and is necessary for their 
spread to distant organs. The process 
of metastasis requires changes in cell 
adhesion, increased cell migration, and 
angiogenesis. To determine the effect 
of ZD6474 on cell invasion and migra-
tion, cells were treated and Boyden 
chamber assays were performed. These 
results show that ZD6474 effectively 
blocked cell invasion and migration 
of MCF-7, T-47D and MDA-MB-231 
cells (Fig. 4C and D). Thus, the EGFR 
and VEGFR-2-TKI ZD6474 may be 
an effective tool in inhibiting tumor 
formation as well as blocking breast 
cancer invasion and potentially metas-
tasis. Additionally, there was a decrease 
in CD-31 staining in MDA-MB-231 
xenografts after ZD6474 treatment 
(Fig. 6A), suggesting its inhibitory 
effect on angiogenesis.
Antitumor effect of ZD6474 in 
nude mice. MDA-MB-231 xenografts 
were developed in nude mice to study 
the antitumor effect of ZD6474 on 
tumor growth. There was a significant 
reduction in tumor size and tumor 
mass (p = 0.0002, n = 5, unpaired 
t-test) (Fig. 5A and B) after ZD647 
treatment compared to control. Tumor 
volume was significantly reduced 
(Fig. 5C). There was significant 
growth delay in attending tumor vol-
ume, RT
4
 in the treatment groups as 
compared to control groups (Fig. 5D). 
The growth delay was almost 20 d 
(Table 2) between two groups. Using 
survival curve analysis by log-rank 
Figure 1. Dose-dependent growth inhibi-
tory effects of ZD6474 on breast cancer 
cell lines. MCF-7, MDA-MB-231, T-47D and 
ZR-75-1 cells were treated with ZD6474 
and incubated for 3 d and MTT assays 
were performed. (A) points, average ± 
sD of three different experiments each 
performed in triplicate. Cell cycle analysis 
was performed by treating cells with an 
IC50 dose of ZD6474. (B) Representative 
histogram plot of breast cancer cells 
treated with ZD647 for 6 (second histo-
gram from the left), 12 and 24 (extreme 
right) h along with control (extreme left) 
(0.1% DMsO). (C) Western blotting of MCF-
7 and MDA-MB-231 treated with ZD6474 
for the indicated time periods along with 
control (C). β-actin was used as an internal 
probe for equal loading. Representative 
data of three independent experiments.
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indicated that ZD6474 inhibits angiogenesis and proliferation in 
vitro as well as in vivo in lung, ovarian, thyroid and breast car-
cinoma cells. We presently studied the detailed mechanisms of 
growth inhibition along with its additional apoptotic activity in 
breast cancer. ZD6474 suppressed cellular proliferation by inhib-
iting phosphorylation of EGFR, VEGFR-2, Akt and MAPK in 
vitro. In addition, it induced apoptosis by increasing the pro-
apoptotic Bax, inhibiting anti-apoptotic Bcl-2, thus shifting the 
balance from survival to apoptosis. This dual TKI also inhibited 
anchorage-independent colony formation and chemoinvasion 
in vitro. The oral administration of ZD6474 in alternative days 
significantly reduced tumor size and volume in nude mice con-
taining human MDA-MB-231 xenografts. There was a decrease 
in Ki-67 positivity and an increase in DNA fragmentation as 
shown by antibody staining and TUNEL assay, respectively, 
in ZD6474-treated compared to control mice bearing tumor, 
confirming a role as an antiproliferative and apoptotic promot-
ing agent. IHC analyses further showed the in vivo inhibition 
of activated EGFR and VEGFR signaling pathways and down-
stream Akt and MAPK activities by ZD6474 in mice bearing 
MDA-MB-231 tumors.
In vitro, ZD6474 induced significant growth inhibition of 
breast cancer cells, including MCF-7, MDA-MB-231, T-47D 
and ZR-75-1. These cell lines express both EGFR and VEGFR 
with ZR-75-1 expressing VEGFR with low or no expression 
of EGFR,23,24 indicating the role of VEGFR in tumor growth 
that is distinct from angiogenesis. In addition, VEGFR-1 and 
VEGFR-2 expression has been detected on various tumor cells, 
such as leukemias, melanomas, non-small cell lung carcinomas, 
prostate carcinomas and breast carcinomas.25-28 The significance 
of this expression has not been studied in detail in breast cancer. 
Therefore, it is conceivable that angiogenic factors support tumor 
growth not only by inducing angiogenesis, but also by acting 
directly through VEGFR-1 and VEGFR-2 expressed on breast 
carcinomas. Moreover, VEGF overexpression was observed and 
shown to be regulated by hypoxia, which is a common feature of 
most solid tumors, including those of breast and this protein is 
highly expressed in metastastic cells.29 Thus, VEGFR inhibitors 
may inhibit autocrine VEGFR-2 signaling in addition to inhibiting 
paracrine signaling with stromal and endothelial cells surround-
ing the tumor. Consistent with this hypothesis, recent studies 
have shown that for certain leukemias, VEGFR-1 may be essen-
tial for tumor cell growth by promoting a VEGF-A/VEGFR-1 
autocrine loop, that when disrupted induces tumor growth arrest 
and apoptosis.26,27 In breast cancer cell lines, increased survival 
and mitogenic signals are promoted by VEGF-A, but the receptor 
and mechanisms responsible for these observed activities have not 
been fully characterized.29,30
In this study, we also report that ZD6474 is an inhibi-
tor of EGFR tyrosine kinase. This inhibition translated into 
dose- and time-dependent antiproliferative effects of ZD6474 
in breast carcinoma cells. We demonstrate that ZD6474 blocks 
EGF-mediated proliferation of cells in vitro, as well as in vivo. 
Furthermore, our studies agree with studies showing ZD6474, a 
potent inhibitor of VEGFR-2, can inhibit EGFR phosphoryla-
tion in cells devoid of VEGFRs and which overexpress EGFR.21 
(Mentel-Cox) test, there was a significant difference (p = 0.0019) 
between control and ZD6474 treatment in attending tumor vol-
ume, RT
4
. IHC analysis of Ki-67 confirmed the antiproliferative 
function and TUNEL assays confirmed the apoptosis promoting 
effects of ZD6474 (Fig. 6A).
ZD6474 blocks epidermal growth factor receptor and 
vascular endothelial growth factor receptor signaling in 
breast carcinoma cells growing subcutaneously in nude mice. 
Immunohistochemical studies revealed that the level of expression 
of EGFR and VEGFR did not vary significantly among tumors 
from control and ZD6474 treatment groups (Fig. 6B). In contrast, 
EGFR and VEGFR activation differed markedly in tumors from 
the mice treated with ZD6474 in comparison with the control ani-
mals. When antibodies specific to tyrosine-phosphorylated (acti-
vated) EGFR and VEGFR were used, both receptors showed high 
levels of phosphorylation in the absence of ZD6474 treatment. 
Levels of phosphorylation of EGFR and VEGFR-2VEGFR-2 were 
markedly reduced in tumors treated with ZD6474. The status of 
two of the major downstream targets of EGFR and VEGFR path-
ways, Akt and MAPK, was also assessed by immunohistochemical 
analysis. There were only negligible changes in the levels of expres-
sion of total Akt and MAPK proteins in the treatment vs. con-
trol groups. However, the phosphorylation status of both kinases, 
although high in the control, was distinctly downregulated in 
the mice treated with ZD6474 (Fig. 6B). These results correlate 
directly with those of in the in vitro experiments.
Discussion
In our study, ZD6474 effectively inhibited cellular proliferation 
and induced apoptosis of breast carcinoma cells. Previous reports 
Table 1. Cell cycle study of breast cancer cells
Cell
Time 
(h)
G0/G1 (%) S (%) G2/M (%)
MCF-7
0 66.555 ± 3.359 25.450 ± 2.800 8.055 ± 0.488
6 68.375 ± 2.397 24.435 ± 3.712 7.185 ± 1.038
12 84.675 ± 0.615 9.620 ± 5.119 5.805 ± 4.377
24 90.245 ± 0.474 7.040 ± 1.557 2.715 ± 2.029
MDA-
MB-231
0 64.730 ± 2.998 19.525 ± 2.185 15.645 ± 5.042
6 69.605 ± 2.807 17.950 ± 0.396 12.450 ± 2.418
12 75.805 ± 1.068 13.280 ± 1.414 10.915 ± 2.482
24 82.095 ± 5.084 10.685 ± 2.581 7.220 ± 2.517
T-47D
0 60.755 ± 3.274 21.755 ± 1.563 17.040 ± 1.075
6 65.730 ± 3.917 16.910 ± 2.744 17.730 ± 0.651
12 75.215 ± 0.615 8.235 ± 2.086 16.555 ± 2.694
24 75.365 ± 1.718 8.880 ± 0.834 15.750 ± 2.546
ZR-75-1
0 62.123 ± 1.327 21.500 ± 2.121 15.439 ± 3.449
6 67.245 ± 1.326 17.210 ± 0.071 14.608 ± 1.255
12 72.124 ± 0.619 15.060 ± 0.085 12.378 ± 0.535
24 81.182 ± 0.843 13.060 ± 0.085 7.354 ± 0.656
Cells were treated with ZD6474 for indicated time (hours) and analyzed 
by flow cytometry. Representative mean (±sD) of three independent 
experiments.
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The phosphorylation status of two major downstream targets 
of EGFR and VEGFR pathways, Akt and MAPK, is downregu-
lated in vitro as well as in vivo after ZD6474 treatment. This 
finding is in agreement with previous studies.31 Expression of 
phosphorylated Akt at Ser-473 in breast tumors is significantly 
associated with HER-2, ER and proliferating index Ki-67,32 and 
in patients prone to relapse with distant metastases.33 Inhibition of 
Akt phosphorylation by a novel Akt inhibitor KP-372-1 success-
fully suppressed cellular growth and induced apoptosis in thyroid 
cancer cells.34 The expression level of MAPK1/2 increases mark-
edly in breast cancer tissues in comparison to normal tissues and 
is strongly related with axillary lymph node metastasis.35 MAPK 
is a prognostic and predictive factor even in cases of triple nega-
tive breast cancers and the elevated level of activated MAPK is 
associated with shorter overall survival (OS).36 Moreover, in vitro 
activated pERK/MAPK is expressed in highly metastatic poten-
tial cells in comparison to non-metastatic MCF-7 cells.37 MAPK 
inhibitors like U0126 and CI-1041 decreased phosphorylated 
It is speculated that ZD6474 could inhibit angiogenesis more 
efficiently than treatment with a selective anti-VEGFR agent, 
because in addition to a direct inhibitory effect on VEGFR-2 
signaling, it would also have an indirect effect on angiogenesis via 
blockade of EGFR-induced paracrine production of angiogenic 
growth factors such as VEGF, bFGF and TGFα by cancer cells. 
Moreover, breast tumor formation and progression depends not 
only on tumor cells, but also on microenvironment consisting 
of additional infiltrating cells mainly macrophages, endothelial 
cells, and hematopoetic cells, at the site of neovascularization. 
It is also speculated that ZD6474 could block tumor prolifera-
tion more efficiently than selective anti-EGFR agents, because in 
addition to inhibiting EGFR, it will also have an indirect effect 
on cell proliferation by depriving tumors of growth factors and 
nutrients normally supplied by the endothelial cells. The antitu-
mor and anti-angiogenesis role of ZD6474 is mainly responsible 
for enhanced anticancer activity of ZD6474 as evident from 
both in vivo as well as in vitro experiments.
Figure 2. ZD6474 induces apoptosis in breast cancer cells. MCF-7, MDA-MB-231, T-47D and ZR-75-1 cells were treated with ZD6474 for the indicated 
time in hours. Flow-cytometry-based assays were done to measure the content of hypo-diploid cells (apoptosis). (A) Data represents values, each  
performed in triplicate; Bars, sD. *, ** and *** represent level of significance with p (<0.05) with respect to control. (B) DNA laddering in MCF-7 and 
MDA-MB-231 cells treated with ZD6474. (C) Fluorescent microscopy of MCF-7 and MDA-MB-231 cells treated with ZD6474 along with control. (D) West-
ern blotting of breast cancer cells treated with ZD6474 for the indicated time in hours. Representative figures of three independent experiments.
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and cytocidal agent. It inhibits transition from G
1
 to S phase as 
confirmed by flow cytometry and western blotting. There is a 
decrease in both cyclin D1 and cyclin E. Cyclin D1 and cyclin 
E are associated with breast cancer progression, early relapse and 
poor prognosis. Cyclin D1 null mice are resistant to mammary 
carcinomas induced by the neu and ras oncogenes, indicating an 
essential role for cyclin D1 in the development of some mam-
mary cancers.40 Therefore, blocking cyclin D1 expression by 
ZD6474 may represent a more specific and less toxic means of 
treating breast cancer.
MAPK and reduced cell proliferation of follicular thyroid cancer 
and breast cancer cells in vitro and in vivo.38,39 Our results con-
firm that ZD6474 can be used to inhibit the MAPK/ERK and 
Akt pathways responsible for human breast cancer tumorigenesis 
and progression.
The downstream targets of ERK/MAPK and Akt/PI3K path-
ways are cyclin and cyclin-dependent kinases (Cdk), and apop-
tosis regulators. The balance between cell division and apoptosis 
controls the fate of a tumor when exposed to an anticancer 
agent. Our results suggest that ZD6474 is both a cytostatic 
Figure 3. ZD6474 inhibits eGFR and VeGFR signaling pathways. (A) Western blotting of MCF-7 and MDA-MB-231 cells treated with ZD6474 for the  
indicated time and probed with anti-eGFR, VeGFR-2 and p53. (B) Autophosphorylation of eGFR, VeGFR-2, MApK and Akt was evaluated in MCF-7,  
MDA-MB-231 and T-47D breast cancer cells growing in vitro in serum-free medium and stimulated with recombinant human eGF (25 ng/mL) for  
30 min in the presence or absence of ZD6474. β-actin protein expression was used as an internal probe for equal loading. Representative of three  
independent experiments.
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In summary, we show that simultaneously blocking EGFR 
and VEGFR signaling by ZD6474 can significantly inhibit cell 
proliferation and induce apoptosis in breast cancer cells. ZD6474 
also inhibits angiogenesis and invasion in vitro. Moreover, 
ZD6474 significantly reduced tumor size and mass in nude mice 
bearing human breast cancer xenografts. These data support fur-
ther development of ZD6474 for clinical use for the treatment 
of breast cancer patients expressing higher level of EGFR and 
VEGFR. By inhibiting both signaling pathways simultaneously, 
a greater than additive growth inhibitory and antitumor effect 
will be generated in breast cancers, thereby resulting in improved 
clinical efficacy.
Materials and Methods
Cell lines. Human breast cancer cell lines MCF-7 and 
MDA-MB-231 cells were cultured in Dulbecco’s Modified 
Apart from its inhibitory effect on cell cycle regulatory 
proteins, ZD6474 also induces apoptosis in breast cancer cells. 
Apoptosis is regulated by Bcl-2 gene family members. We 
observed an increase in the expression of Bax and a downreg-
ulation in the expression of Bcl-2. ZD6474 also decreased the 
expression of Bcl-x
L
 (data not shown) in breast cancer cells. An 
increase in Bcl-2 shifts the balance in favor of cell survival and 
can mediate resistance to chemotherapy. The tumorigenic poten-
tial of Bcl-2 has been shown in animal models41,42 and is sup-
ported by the finding of overexpression of Bcl-2 in a variety of 
solid organ tumors and in lymphomas.43,44 Moreover overexpres-
sion of Bcl-2 is associated with metastatic potential of breast can-
cer cells, since Bcl-2 transfectants or Bcl-2 overexpressing clones 
secrete MMP-9 and MMP-2, leading to an increase in invasion 
and metastasis.45 There are also reports suggesting that ZD6474 
enhances the antitumor effects of taxanes and ionizing radiation 
in glioblastoma, breast, colon and ovarian cancers.18
Figure 4. ZD6474 inhibits anchorage-independent cell proliferation, chemoinvasion and migration. MCF-7, T-47D and MDA-MB-231 cells were treated 
with ZD6474. (A) Representative figure of soft agar growth of breast cancer cells treated with ZD6474 and/or eGF along with control (without eGF and 
ZD6474). (B) Data represent the average (±sD) number of colonies of three different experiments, each performed in triplicate. (C) Representative 
figure of Boyden chamber assay for breast cancer cells treated with ZD6474 along with control. (D) Data represent the average percentage of cells 
(±sD) invading the Boyden chamber inserts coated with Matrigel of three different experiments, each performed in triplicate. Bars, sD. *, ** and *** 
represent level of significance with p (<0.05) with respect to control.
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anti-Bax, anti-caspase-3, mouse anti-p53, anti-Bcl2, anti-caspase-7, 
horseradish peroxidase-conjugated goat anti-rabbit IgG and goat 
anti-mouse IgG, alkaline phosphatase-conjugated goat anti-rabbit 
IgG and goat anti-mouse IgG (Santa Cruz Biotechnology, Santa 
Cruz, CA). Chemiluminescent peroxidase substrate, BCIP/NBT 
Propidium iodide (PI) and 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) (Sigma-Aldrich, St. Louis, 
MO). Stock solutions of PI and MTT were prepared by dissolving 
1 mg of each compound in 1 mL PBS in incomplete medium, 
respectively. The solution was protected from light, stored at 4°C, 
and used within 1 mo. Stock concentrations of 10 mg/ml RNase 
A (Sigma) were prepared and kept at -20°C.
Cell viability. Cell viability was determined by MTT-dye reduc-
tion assay as described by Mosmann.19 The cell suspensions were 
Eagle’s Medium: nutrient mixture F-12 (Ham) (D-MEM/F-12) 
with 15 mM HEPES buffer, L-glutamine, pyridoxine hydrochlo-
ride, supplemented with 1.2 g sodium bicarbonate, antibiotics 
(10,000 U/L penicillin and 10 mg/L streptomycin) and 10% 
FBS. ZR-75-1 and T-47D cells were grown in RPMI-1640, sup-
plemented with 10% FBS. Cells were incubated at 37°C in a 5% 
CO
2
 and 95% humidified incubator.
Reagents. A stock solution of 20 mM of ZD6474 was dis-
solved in DMSO, stored at -20°C, and diluted in fresh medium 
just before use. For western blot analysis, the following antibodies 
were used: polyclonal rabbit anti-EGFR, anti-VEGFR-2, anti-
pEGFR, anti-pVEGFR-2, monoclonal rabbit anti-pAkt, anti-
pMAPK, anti-Akt and anti-MAPK (Cell Signaling Technology, 
Beverly, MA), monoclonal rabbit anti-PARP, anti-cytochrome-c, 
Figure 5. Antitumor activity of ZD6474 in MDA-MB-231 human breast carcinoma xenografts. Mice bearing MDA-MB-231 xenografts were treated with 
ZD6474 (50 mg/kg body weight) once orally in alternative days starting 1 week after tumor cell implantation and continued for 5 weeks. (A) Tumor  
volume was prominent and large in case of vehicle vs. the treatment groups. Mice were sacrificed and tumor masses of vehicles and in treatment 
groups were weighed. (B) Bar graph with se represents tumor mass in grams after 5 w of tumor cells implantation. There was significant difference  
(p = 0.0002, n = 5; unpaired t-test) in tumor mass between control and treatment groups. Antitumor effect of ZD6474 was compared by tumor 
response curves. (C) Data points represent mean (±se) tumor volume for vehicle and treatment groups (n = 5). (D) Diagrammatic representation of 
ZD6474 treatment on the time taken for each individual tumor within the treatment groups to achieve RT4, along with control groups.
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Figure 6. Immunohistochemistry of ZD6474-treated MDA-MB-231 human breast carcinoma xenografts. paraffin-embedded sections of MDA-MB-231 
bearing tumors in nude mice were processed and IhC was done. (A) IhC of Ki-67, CD-31 and TUNeL (Terminal deoxynucleotidyl transferase dUTp nick 
end labeling) assays were performed. (B) IhC of peGFR (Tyr1068), pVeGFR-2 (Tyr1175), pMApK (Thr42/22), pAkt (ser473) along with total eGFR, VeGFR-2, 
MApK and Akt. Representative of three independent experiments. Bar represents 10 µm.
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Western blot analyses of pEGFR/EGFR, pVEGFR-2/
VEGFR-2, pMAPK/MAPK, pAkt/Akt. Cells were plated in 
a six-well plate at a concentration of 4 x 105 cells per well and 
incubated in 10% FBS medium overnight. The next day, the 
cells were washed and incubated in serum-free medium for 
24 h. The experimental wells were treated with ZD6474 at a con-
centration of 10 µM, whereas the control wells were treated with 
0.1% DMSO for 1 h. Then, cells were activated with recombi-
nant human EGF (25 ng/mL) for 30 min, washed with PBS, and 
scraped with lysis buffer as described previously. The proteins 
(50 µg) were resolved on SDS-PAGE and western blotting was 
performed.
Colony formation assays. Cells (2 x 104 cells/well) were sus-
pended in 1 ml of 0.36% bactoagar, supplemented with com-
plete culture medium. This suspension was layered over 1 ml of 
0.6% agar-medium base layer in 6-well plates, and treated with 
ZD6474 at respective IC
50
 dose alone and/or in combination with 
25 ng/µl EGF, along with the untreated control (0.1% DMSO) 
for 3 d. After 14 to 21 d, cells were stained with crystal violet 
(0.005%) and colonies >0.05 mm were counted as described 
previously.21
Boyden chamber assay. To test the invasive behavior of 
treated cells, 8-µm filters were coated with Matrigel (20 µg/ 
filter) and placed in Boyden chambers. Cells (1 x 105), suspended 
in DMEM/F-12 containing 0.1% BSA and treated with ZD6474, 
were added to the top chamber. Conditioned medium from 
mouse fibroblast NIH3T3 cells was used as a source of chemoat-
tractant and placed in the bottom compartment of the Boyden 
chambers. After 24 h incubation at 37°C, non-invaded cells were 
scraped off, and the cells that had migrated to the lower surface 
of the filter inserts were fixed with 100% methanol for 10 min and 
stained with H&E.22 The results are expressed as the percent of 
migrated cells as compared to the control (untreated cells). Each 
experiment was performed three times with triplicate samples.
In vivo xenografts. Tumor response to ZD6474 was studied 
using a nude mouse model of breast cancer. The animal research 
protocol was approved, and mice were maintained in accor-
dance with the institutional (IACUC) guidelines of Virginia 
Commonwealth University, School of Medicine, and mice 
were acclimatized at the Virginia Commonwealth University 
Animal Facility for 1 w prior to injection with MDA-MB-231 
cells. Exponentially growing MDA-MB-231 cells were harvested 
and a tumorogenic dose of 2.5 x 106 cells in Matrigel (0.5 mg/
ml) were injected s.c. in 6–7 w-old female athymic BALB/c 
(nu+/nu+) mice. Tumors were allowed to grow for 7 d; all of the 
mice then were weighed, and all of the tumors were measured 
using microcalipers.
Tumor volume was calculated using the formula (A) (B2) π/6, 
where A was the length of the longest aspect of the tumor, and 
B was the length of the tumor perpendicular to A. All mice were 
randomized into two groups, containing five mice per group. 
Group 1, the control group received 1% poysorbate resuspended 
in deionized water, and the second group was treated with 
ZD6474 (50 mg/kg body weight) in alternative days by mouth 
at 0.1 ml/10 g body weight for 4 w. The dose was selected based 
on previous experiments.17,18 Tumors were measured at the end of 
dispensed (200 µl) in quadruplicate into 96-well tissue culture 
plates at an optimized concentration of 1 x 104 cells/well in com-
plete medium. Twenty-four hours after seeding, cells were treated 
with 10 nM to 50 µM of ZD6474 or 0.1% DMSO (control), and 
incubated for 72 h. Cell viability was measured at 540 nm.
Cell cycle and apoptosis. Cells were treated at their respec-
tive IC
50
 values 24 h after seeding in 60-mm tissue culture plates. 
Temporal response curves were determined from 6–24 h for cell 
cycle study and 6–72 h for apoptosis study, along with the con-
trol (0.1% DMSO). After treatment, cells were collected and 
washed in phosphate buffer saline (PBS) and incubated in 70% 
ethanol for 45 min at 4°C or kept at -20°C overnight for fixa-
tion. Cells were centrifuged, washed and then incubated with 
PI solution (40 µg/ml PI, 100 µg/ml RNase A in PBS) at 37°C 
for 1 h. Apoptotic cells were determined by their hypochromic 
sub-diploid staining profiles. The distribution of cells in the dif-
ferent cell cycle phases was analyzed from the DNA histogram 
using Becton-Dickinson FACSCaliber flow cytometer and Cell 
Quest software.
DNA laddering. For the DNA fragmentation assays, 2 x 106 
cells were seeded in 100-mm plates and incubated for 24 h in 10% 
FBS medium. Cells were treated with ZD6474 at their respective 
IC
50
 concentration for 6–72 h, along with control, in incomplete 
medium. Both floating and attached cells were collected, washed 
with phosphate-buffered saline, and resuspended in 0.5 mL of 
lysis buffer (20 mM Tris HCl [pH 8], 10 mM EDTA [pH 8] and 
0.5% Triton X-100) and low molecular weight DNA was isolated 
as described previously.20 DNA was resuspended in Tris-EDTA 
buffer (TE), treated with RNase A (1 mg/ml) at 37°C for 1 h, 
and total DNA was analyzed using 1.5% agarose gel and visual-
ized by ethidium bromide staining of the gel.
Western blot analysis of growth regulatory proteins and 
apoptosis proteins. Cells were treated with ZD6474 at their IC
50
 
dose for the indicated time periods in hours. The cells were then 
scraped and lysed in Nonidet P-40 lysis buffer [(50 mM Tris HCl 
(pH 8.0)], 137 mM sodium chloride, 10% glycerol, 1% Nonidet 
P-40, 50 mM sodium fluoride, 10 mM EDTA] containing 1 mM 
sodium vanadate, 1 mM phenylmethylsulfonyl fluoride, and pro-
tease cocktail inhibitor. Cell extracts were separated on sodium 
dodecyl sulfate-polyacrylamide electrophoretic gel (SDS-PAGE) 
and transferred to nitrocellulose membranes, which were blocked 
with 2% BSA and probed with the appropriate antibodies and 
secondary antibodies. Membranes were then developed using 
enhanced chemiluminescence or alkaline phosphatase-based 
colorimetric methods.
Table 2. Influence of ZD6474 on MDA-MB-231 xenograft tumor growth
Treatment
RT2  
(days ± SE)*
RT4  
(days ± SE)
Growth delay 
(days ± SE)
Vehicle 5.06 ± 0.30 10.11 ± 0.61 NA
ZD6474 (50 mg/kg) 14.71 ± 2.71 ζ 29.41 ± 5.43 19.89 ± 5.56
*Doubling times were calculated by using the exponential growth 
equation of each individual tumor with in the treatment group. ζ Based 
upon n = 5; one tumor didn’t achieve RT4 (four times that of initial 
tumor volume at the start of the treatment) with in 28 d after treatment 
with ZD6474, and with almost complete loss of tumor mass.
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ABC reagent and developed using DAB as a substrate. The slides 
were washed again in TBST twice for 10 min, dehydrated by 
using ethanol, followed by washing in xylene, and mounted with 
D.P.X mountant (MERCK).
Immunofluorescence studies were done using a confocal 
microscope (Olympus FluoView FV1000, Version 1.7.1.0). 
Excitation wavelength at 543 nm, emission wavelength at 
578 nm, 30% transmissivity, 596 (V) PMT voltages were set 
for image acquisition in LSM mode. Images were captured 
digitized using FLUOVIEW 1000 (Version 1.2.4.0) imaging 
software.
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every week. After 4 w of treatment, mice were euthanized, and 
the tumors were measured again. During the experiment, mice 
were examined twice weekly for weight loss.
Immunohistochemistry (IHC). Immunohistochemistry 
was performed with the following antibodies: rabbit anti-
pEGFR (Tyr1068), anti-EGFR, anti-pVEGFR-2 (Tyr1175), 
anti-VEGFR-2, anti-pMAPK (Thr202/Tyr204), anti-MAPK, 
anti-pAKT (Ser473) and anti-AKT and monoclonal mouse anti-
CD31 (Cell Signaling Technology), mouse anti-Ki-67 (Santa 
Cruz). For antibody staining, paraffin-embedded sections were 
first deparafinized in xylene. Excess xylene was removed by wash-
ing the slides in a series of ethanol solutions. Antigen unmasking 
was done by boiling the tissue with 10 mM Sodium citrate (pH 
6.0), followed by maintaining the temperature at sub-boiling 
90°C for 30 min. The slides were cooled at RT for 30 min, and 
washed thrice with dH
2
O. Endogenous peroxidase blocking was 
done with 3% H
2
O
2
 followed by protein blocking using 2% BSA 
in TBST (protein-blocking solution). After blocking, the pri-
mary antibody (1:200 dilutions) was added and incubated for 
1 h at RT. The slides were then washed with TBST, and incu-
bated with rhodamine-conjugated anti-rabbit IgG (1:400 dilu-
tions, Santa Cruz) for 1 h at RT in dark or biotinylated secondary 
antibody (Vectastain Elite ABC kit, dilutions were made accord-
ing to the manufacturer’s instructions), followed by addition of 
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